Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients

Finerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients The Phase III study FIND-CKD, evaluating the efficacy and safety of finerenone (Kerendia™) versus…

Read MoreFinerenone Achieves Primary Endpoint in Pivotal Phase III FIND-CKD Trial for Non-Diabetic Chronic Kidney Disease Patients

Pfizer Reports Positive Phase 2 Topline Results for Atirmociclib, a Next-Generation CDK4 Inhibitor, in Second-Line Metastatic Breast Cancer

Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1…

Read MorePfizer Reports Positive Phase 2 Topline Results for Atirmociclib, a Next-Generation CDK4 Inhibitor, in Second-Line Metastatic Breast Cancer

Novartis’ Cosentyx® Gains FDA Approval for Patients 12 and Older With Moderate-to-Severe Hidradenitis Suppurativa

Novartis’s Cosentyx gains U.S. Food and Drug Administration approval for patients aged 12+ with moderate-to-severe Hidradenitis Suppurativa. Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval…

Read MoreNovartis’ Cosentyx® Gains FDA Approval for Patients 12 and Older With Moderate-to-Severe Hidradenitis Suppurativa

Johnson & Johnson Reports Encouraging First-in-Human Results for Erda-iDRS (TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating…

Read MoreJohnson & Johnson Reports Encouraging First-in-Human Results for Erda-iDRS (TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing…

Read MoreWuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership
Celltrion

Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Boosting Scale from Development to Commercialization

Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Enhancing Economies of Scale from Development to Manufacturing and Direct Commercialization Celltrion announced today that it will immediately incorporate newly announced…

Read MoreCelltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Boosting Scale from Development to Commercialization